Donald Wiebe1, Neil Binkley. 1. University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705.
Abstract
CONTEXT: We report the presence of substantial concentrations of 3-epi-25(OH)D3 in two patients and a third patient with 3-epi-25(OH)D2. PATIENTS: The first patient, a 66-year-old female receiving cholecalciferol 4000 IU daily was originally found to have 53 ng/mL of 25(OH)D3 and almost an equal amount of 3-epi-25(OH)D3. Subsequently, the patient had four additional samples, each of which has similar levels of both 25(OH)D3 and 3-epi-25(OH)D3. The second patient, a 7-year-old male receiving cholecalciferol 1000 IU daily, had a 25(OH)D3 concentration of 37 ng/mL and 3-epi-25(OH)D3 of approximately 10 ng/mL. The third and most intriguing patient, a 55-year-old female was receiving ergocalciferol 50,000 IU twice weekly for approximately 3 months, at which time her serum 25(OH)D2 was 64 ng/mL and her 3-epi-25(OH)D2 was approximately 32 ng/mL. This patient's physician changed her vitamin D therapy to cholecalciferol 1000 IU daily, discontinuing ergocalciferol, and a second specimen was collected 5 months later. Analysis of this last specimen found both 25(OH)D3 and 25(OH)D2 at concentrations of 12 and 24 ng/mL respectively, plus corresponding 3-epimer peaks for both 25(OH)D3 and 25(OH)D2 observed chromatographically. CONCLUSION: The presence of a substantial concentration of 3-epi-25(OH)D in these three patients documents that one cannot assume 3-epi is a trivial metabolite of 25(OH)D for all patients. In addition, the appearance of 3-epi-25(OH)D3 when the last patient changed her vitamin D supplementation from ergocalciferol to cholecalciferol demonstrates that the 3-epimer is probably an endogenous metabolite of 25(OH)D in humans.
CONTEXT: We report the presence of substantial concentrations of 3-epi-25(OH)D3 in two patients and a third patient with 3-epi-25(OH)D2. PATIENTS: The first patient, a 66-year-old female receiving cholecalciferol 4000 IU daily was originally found to have 53 ng/mL of 25(OH)D3 and almost an equal amount of 3-epi-25(OH)D3. Subsequently, the patient had four additional samples, each of which has similar levels of both 25(OH)D3 and 3-epi-25(OH)D3. The second patient, a 7-year-old male receiving cholecalciferol 1000 IU daily, had a 25(OH)D3 concentration of 37 ng/mL and 3-epi-25(OH)D3 of approximately 10 ng/mL. The third and most intriguing patient, a 55-year-old female was receiving ergocalciferol 50,000 IU twice weekly for approximately 3 months, at which time her serum 25(OH)D2 was 64 ng/mL and her 3-epi-25(OH)D2 was approximately 32 ng/mL. This patient's physician changed her vitamin D therapy to cholecalciferol 1000 IU daily, discontinuing ergocalciferol, and a second specimen was collected 5 months later. Analysis of this last specimen found both 25(OH)D3 and 25(OH)D2 at concentrations of 12 and 24 ng/mL respectively, plus corresponding 3-epimer peaks for both 25(OH)D3 and 25(OH)D2 observed chromatographically. CONCLUSION: The presence of a substantial concentration of 3-epi-25(OH)D in these three patients documents that one cannot assume 3-epi is a trivial metabolite of 25(OH)D for all patients. In addition, the appearance of 3-epi-25(OH)D3 when the last patient changed her vitamin D supplementation from ergocalciferol to cholecalciferol demonstrates that the 3-epimer is probably an endogenous metabolite of 25(OH)D in humans.
Authors: Alex J Brown; Cynthia S Ritter; A S Weiskopf; P Vouros; Gino J Sasso; Milan R Uskokovic; Guochun Wang; G Satyanarayana Reddy Journal: J Cell Biochem Date: 2005-10-15 Impact factor: 4.429
Authors: N J Koszewski; T A Reinhardt; D C Beitz; J L Napoli; E G Baggiolini; M R Uskokovic; R L Horst Journal: Anal Biochem Date: 1987-05-01 Impact factor: 3.365
Authors: M L Siu-Caldera; H Sekimoto; A Weiskopf; P Vouros; K R Muralidharan; W H Okamura; J Bishop; A W Norman; M R Uskoković; I Schuster; G S Reddy Journal: Bone Date: 1999-05 Impact factor: 4.398
Authors: Virender K Rehan; John S Torday; Sara Peleg; Lynn Gennaro; Paul Vouros; James Padbury; D Sunita Rao; G Satyanarayana Reddy Journal: Mol Genet Metab Date: 2002-05 Impact factor: 4.797
Authors: Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley Journal: Br J Clin Pharmacol Date: 2018-07-17 Impact factor: 4.335
Authors: Karen W Phinney; Susan S-C Tai; Mary Bedner; Johanna E Camara; Rosalind R C Chia; Lane C Sander; Katherine E Sharpless; Stephen A Wise; James H Yen; Rosemary L Schleicher; Madhulika Chaudhary-Webb; Khin L Maw; Yasamin Rahmani; Joseph M Betz; Joyce Merkel; Christopher T Sempos; Paul M Coates; Ramón A Durazo-Arvizu; Kurtis Sarafin; Stephen P J Brooks Journal: Anal Chem Date: 2017-04-13 Impact factor: 6.986
Authors: Niek F Dirks; Hubert W Vesper; Antonius E van Herwaarden; Jody M W van den Ouweland; Ido P Kema; Johannes G Krabbe; Annemieke C Heijboer Journal: Clin Chim Acta Date: 2016-08-25 Impact factor: 3.786